Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment

被引:1
作者
Dogru, Mustafa Vedat [1 ]
Sezen, Celal Bugra [1 ]
Aker, Cemal [1 ]
Erdogu, Volkan [1 ]
Saydam, Ozkan [1 ]
Olcmen, Aysun [1 ]
Cansever, Levent [1 ]
Metin, Muzaffer [1 ]
机构
[1] Yedikule Chest Dis & Thorac Surg Training & Res H, Dept Thorac Surg, Istanbul, Turkey
来源
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2021年 / 29卷 / 02期
关键词
Induction treatment; lung cancer; pathological complete response; PATHOLOGICAL COMPLETE RESPONSE; STAGE-IIIA; NEOADJUVANT THERAPY; CHEMOTHERAPY; SURGERY; CHEMORADIATION; CHEMORADIOTHERAPY; PNEUMONECTOMY; SURVIVAL;
D O I
10.5606/tgkdc.dergisi.2021.19956
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: This study aims to evaluate long-term results of induction treatment and to investigate prognostic factors affecting survival in non-small cell lung cancer patients with a pathological complete response. Methods: Between January 2010 and December 2017, a total of 39 patients (38 males, 1 female; mean age: 56.2 +/- 8.3 years; range, 38 to 77 years) having locally advanced (IIIA-IIIB) non-small cell lung cancer who were given induction treatment and underwent surgery after induction treatment and had a pathological complete response were retrospectively analyzed. Survival rates of the patients and prognostic factors of survival were analyzed. Results: Clinical staging before induction treatment revealed Stage IIB, IIIA, and IIIB disease in three (7.7%), 26 (66.7%), and 10 (25.6%) patients, respectively. The five-year overall survival rate was 61.2%, and the disease-free survival rate was 55.1%. In nine (23.1%) patients, local and distant recurrences were detected in the postoperative period. Conclusion: In patients with locally advanced non-small cell lung cancer undergoing surgery after induction treatment, the rates of pathological complete response are at considerable levels. In these patients, the five-year overall survival is quite satisfactory and the most important prognostic factor affecting overall survival is the presence of single-station N2.
引用
收藏
页码:201 / 211
页数:11
相关论文
共 32 条
[1]   Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment [J].
Akyil, Mustafa ;
Tezel, Cagatay ;
Akyil, Fatma Tokgoz ;
Gurer, Deniz ;
Evman, Serdar ;
Alpay, Levent ;
Baysungur, Volkan ;
Yalcinkaya, Irfan .
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2020, 28 (01) :166-174
[2]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]   Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer [J].
Cerfolio, RJ ;
Bryant, AS ;
Winokur, TS ;
Ohja, B ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2004, 78 (06) :1903-1909
[4]   The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: Who returns to the surgical arena and who survives [J].
Cerfolio, Robert J. ;
Maniscalco, Lee ;
Bryant, Ayesha S. .
ANNALS OF THORACIC SURGERY, 2008, 86 (03) :912-920
[5]   Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival [J].
Cerfolio, Robert James ;
Bryant, Ayesha S. ;
Jones, Virginia L. ;
Cerfolio, Robert Michael .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (04) :718-723
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   Radiomic phenotype features predict pathological response in non-small cell lung cancer [J].
Coroller, Thibaud P. ;
Agrawal, Vishesh ;
Narayan, Vivek ;
Hou, Ying ;
Grossmann, Patrick ;
Lee, Stephanie W. ;
Mak, Raymond H. ;
Aerts, Hugo J. W. L. .
RADIOTHERAPY AND ONCOLOGY, 2016, 119 (03) :480-486
[8]   Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society) [J].
Counago, F. ;
Rodriguez de Dios, N. ;
Montemuino, S. ;
Jove-Teixido, J. ;
Martin, M. ;
Calvo-Crespo, P. ;
Lopez-Mata, M. ;
Samper-Ots, M. P. ;
Lopez-Guerra, J. L. ;
Garcia-Canibano, T. ;
Diaz-Diaz, V ;
de Ingunza-Baron, L. ;
Murcia-Mejia, M. ;
Alcantara, P. ;
Corona, J. ;
Puertas, M. M. ;
Chust, M. ;
Couselo, M. L. ;
del Cerro, E. ;
Moradiellos, J. ;
Amor, S. ;
Varela, A. ;
Thuissard, I. J. ;
Sanz-Rosa, D. ;
Taboada, B. .
LUNG CANCER, 2018, 118 :119-127
[9]   Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Crino, L. ;
Weder, W. ;
van Meerbeeck, J. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2010, 21 :v103-v115
[10]   Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer [J].
DeCamp, MM ;
Rice, TW ;
Adelstein, DJ ;
Chidel, MA ;
Rybicki, LA ;
Murthy, SC ;
Blackstone, EH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (01) :17-27